Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875252 | 0.78 | PRNP (0.42) | PRNPKMT2AMEN1FABP4ALDH1A1 | |
| SCHEMBL2360435 | 0.77 | PRNP (0.32) | PRNPKMT2AMEN1MAOB | |
| SCHEMBL588389 | 0.77 | PRNP (0.53) | PRNPKMT2AFABP4TSHRALDH1A1 | |
| SCHEMBL8495468 | 0.74 | PRNP (0.50) | PRNPKMT2AMEN1FABP4TSHR | |
| SCHEMBL372707 | 0.74 | PRNP (0.40) | PRNPKMT2AMEN1FABP4ALDH1A1 | |
| SCHEMBL4758788 | 0.72 | MAOB (0.36) | PRNPKMT2AMEN1FABP4ALDH1A1 | |
| SCHEMBL9136350 | 0.71 | PRNP (0.56) | PRNPKMT2AMEN1FABP4TSHR | |
| SCHEMBL28482995 | 0.71 | PRNP (0.39) | PRNPKMT2AMEN1FABP4ALDH1A1 | |
| SCHEMBL3170417 | 0.71 | METAP2 (0.48) | TSHRALDH1A1HPGD | |
| SCHEMBL1873518 | 0.71 | KMT2A (0.41) | PRNPKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116363-B2 | Combinations for immune-modulation in cancer treatment | SENHWA BIOSCIENCES, INC. (TW) | 2024-10-15 | — | — | US | disclosed |
| US-20230302436-A1 | OXIDATIVE PROCESSES FOR SELF-HEATING AND PYROPHORIC CATALYSTS CONTAINING ACTIVE METAL SULFIDES, AND MITIGATION OF HALIDE AND POLYTHIONIC ACID STRESS CORROSION CRACKING MECHANISMS IN PROCESS EQUIPMENT | REFINED TECHNOLOGIES, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4189127-A1 | OXIDATIVE PROCESSES FOR SELF-HEATING AND PYROPHORIC CATALYSTS CONTAINING ACTIVE METAL SULFIDES, AND MITIGATION OF HALIDE AND POLYTHIONIC ACID STRESS CORROSION CRACKING MECHANISMS IN PROCESS EQUIPMENT | Refined Technologies, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234937-A | Oxidative process for autothermal and pyrophoric catalysts containing active metal sulfides and mitigation of halide and dithionic acid stress corrosion cracking mechanisms in process equipment | 精炼技术公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022026530-A1 | OXIDATIVE PROCESSES FOR SELF-HEATING AND PYROPHORIC CATALYSTS CONTAINING ACTIVE METAL SULFIDES, AND MITIGATION OF HALIDE AND POLYTHIONIC ACID STRESS CORROSION CRACKING MECHANISMS IN PROCESS EQUIPMENT | REFINED TECHNOLOGIES, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2020081971-A1 | COMBINATIONS FOR IMMUNE-MODULATION IN CANCER TREATMENT | SENHWA BIOSCIENCES, INC. (TW) | 2020-04-23 | — | — | WO | disclosed |
| US-20200123153-A1 | COMBINATIONS FOR IMMUNE-MODULATION IN CANCER TREATMENT | SENHWA BIOSCIENCES, INC. (TW) | 2020-04-23 | — | — | US | disclosed |
| EP-2585059-B1 | USE OF DIBENZOFURANONE DERIVATIVES TO INHIBIT KINASES | JOSE JOACHIM (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-9303005-B2 | Use of dibenzofuranone derivatives to inhibit kinases | JOSE JOACHIM (DE) | 2016-04-05 | — | — | US | disclosed |
| WO-2015053452-A1 | SPLICING REGULATOR CONTAINING CX-4945 AS ACTIVE INGREDIENT | 한국생명공학연구원 | 2015-04-16 | — | — | WO | disclosed |
| EP-2598146-A1 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES | Corning Incorporated (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2585059-A1 | USE OF DIBENZOFURANONE DERIVATIVES TO INHIBIT KINASES | Jose, Joachim (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2537027-A1 | METHODS RELATED TO CASEIN KINASE II (CK2) INHIBITORS AND THE USE OF PURINOSOME-DISRUPTING CK2 INHIBITORS FOR ANTI-CANCER THERAPY AGENTS | Corning Incorporated (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120190620-A1 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES | CORNING INCORPORATED | 2012-07-26 | — | — | US | disclosed |
| WO-2012015599-A1 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES | CORNING INCORPORATED (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011161151-A1 | USE OF DIBENZOFURANONE DERIVATIVES TO INHIBIT KINASES | JOSE JOACHIM (DE) | 2011-12-29 | — | — | WO | disclosed |
| US-20110305706-A1 | Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2011-12-15 | — | — | US | disclosed |
| US-20110207789-A1 | METHODS RELATED TO CASEIN KINASE II (CK2) INHIBITORS AND THE USE OF PURINOSOME-DISRUPTING CK2 INHIBITORS FOR ANTI-CANCER THERAPY AGENTS | CORNING INCORPORATED | 2011-08-25 | — | — | US | disclosed |
| WO-2011103224-A1 | METHODS RELATED TO CASEIN KINASE II (CK2) INHIBITORS AND THE USE OF PURINOSOME-DISRUPTING CK2 INHIBITORS FOR ANTI-CANCER THERAPY AGENTS | CORNING INCORPORATED (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010096751-A1 | COMPOSITIONS AND METHODS FOR TREATING A DISEASE MEDIATED BY SOLUBLE OLIGOMERIC AMYLOID BETA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116363-B2 | Combinations for immune-modulation in cancer treatment | CKS2, LCK, CD274 | PRNP 4120/4885KMT2A 537/4885MEN1 3504/4885 |
| US-20200123153-A1 | COMBINATIONS FOR IMMUNE-MODULATION IN CANCER TREATMENT | LCK, CD274, CKS2 | PRNP 4207/4885KMT2A 606/4885MEN1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.